



Clearbridge Health Limited
37 Jalan Pemimpin #08-05 Mapex Singapore 577177
TEL 65 6251 0136 FAX 65 6251 0132
clearbridgehealth.com

Clearbridge's associate secures commitment of S\$6.6 million in funding in move to unlock shareholder value

- *Clearbridge BioMedics' funding round drew strong interest from healthcare and investing communities*

SINGAPORE – 28 June 2018 – Clearbridge Health Limited (“Clearbridge” or the “Company” and together with its subsidiaries, the “Group”) (明策集团), a healthcare company which focuses on delivering precision medicine in Asia, announced today that the Group’s associated company, Clearbridge BioMedics Pte. Ltd. (“Clearbridge BioMedics”) has secured commitments of S\$6.6 million in funding ahead of its potential listing (“Potential Listing”).

This latest round of funding drew strong interest from oncology medical professionals as well as investors focused on the healthcare and biotechnology spaces. The funds will be utilised for business expansion, technology development, talent recruitment and expenses relating to the Potential Listing.

Mr Jeremy Yee (余斌), Executive Director and Chief Executive Officer of Clearbridge, said, “*Since our listing in December 2017, we have consistently highlighted our focus on creating value for our shareholders, which could also take the form of monetisation of our assets. A successful spin-off of Clearbridge BioMedics will unlock its value which we may then consider distributing to shareholders. We think this is a positive development and will look into the best way to enhance shareholder returns.*”

Clearbridge BioMedics does non-invasive liquid biopsy for real time analysis of cancer cells from a standard blood draw and has developed the ClearCell[®] FX System, one of the world’s first fully automated cell retrieval systems that is now distributed via a network of 12 distributors across the EMEA and APAC regions. The ClearCell[®] FX System has attained various regulatory registrations, such as Europe’s CE IVD certification, USA’s FDA, and China’s CFDA via a Chinese partner. This groundbreaking system provides healthcare professionals with vital and accurate information that allows them to deliver targeted healthcare treatment for patients. In addition to providing clinical benefits, Clearbridge BioMedics’ cancer diagnostics solutions help to lower patients’ medical costs and reduce the inconveniences they encounter.

“*We are pleased that Clearbridge Biomedics has been successful in securing this latest round of funding. This reflects the confidence of the healthcare and investing communities in the good work done by Clearbridge BioMedics over the years. We are very proud of Clearbridge BioMedics’ pioneering work in non-invasive cancer diagnostics and in the wider field of precision medicine,*” added Mr Yee.

-- END --



Clearbridge Health Limited
37 Jalan Pemimpin #08-05 Mapex Singapore 577177
TEL 65 6251 0136 FAX 65 6251 0132
clearbridgehealth.com

About Clearbridge Health Limited

Clearbridge Health Limited is a healthcare company which focuses on delivering precision medicine in Asia. Its business comprises laboratory testing services, medical clinics/centres and strategic equity participation in complementary precision medical technology companies. Through the delivery of precision medicine in Asia, it seeks to empower clinicians and healthcare professionals to make more reliable and accurate diagnoses, provide insights on disease management, and tailor personalised prevention and timely treatment programmes for patients.

For more information, please visit us at www.clearbridgehealth.com.

About Clearbridge BioMedics Pte Ltd

Clearbridge BioMedics Pte Ltd. is a clinical stage cancer diagnostics company that develops and manufactures liquid biopsy systems. Clearbridge BioMedics is based in Singapore and has commercially launched the ClearCell® FX platform to laboratories around the globe. Clearbridge BioMedics has won numerous awards and garnered global recognition for its novel Circulating Tumor Cell (CTC) detection platform technology, the ClearCell® FX System. The ClearCell® FX System and its biochip are utilizing state-of-the-art, non-invasive liquid biopsy to analyze blood samples for circulating tumor cells (CTCs). The device allows for real time analysis of disease before, during, and after treatment, which has become increasingly critical in the new era of targeted cancer therapies.

Clearbridge BioMedics has received ISO 13485 certification in 2011 and the ClearCell® FX System attained CE IVD in 2015 and US FDA Class 1 registration in 2017. In China, the same system is available as China FDA approved Class 1 system as the EasyCell system, through a partnership with MGI (an associate of Beijing Genomics Institute (BGI)).

For more information, visit www.ClearbridgeBioMedics.com.

Issued by and on behalf of Clearbridge Health Limited

August Consulting

Tel: +65 6733 8873

Silvia Heng, silviaheng@august.com.sg

Wrisney Tan, wrisneytan@august.com.sg

Zavier Ong, zavierong@august.com.sg

This press release has been prepared by the Company and its contents have been reviewed by the Company's sponsor, United Overseas Bank Limited (the "Sponsor"), for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited (the "SGX-ST").

The Sponsor has not independently verified the contents of this press release. This press release has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this press release, including the correctness of any of the statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Mr Chia Beng Kwan, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.